title: [Orange skin and xanthomas associated with lycopenaemia in a setting of type III dyslipoproteinemia].
abstract: BACKGROUND
  Type III hyperlipoproteinaemia (HLP) is a rare form of dyslipidaemia characterized by skin lesions such as palmar crease xanthoma and tuberous xanthomas. To our knowledge, there have been no previous reports of yellow-orange discoloration of the skin and xanthomas associated with this disease.
  
  
  METHODS
  A 61-year-old woman consulted for palmar crease xanthoma and tuberous xanthomas of the elbows with odd yellow-orange discoloration. Laboratory investigations demonstrated type-III HLP and a high serum lycopene level. After 14 weeks of lipid-lowering treatment, the xanthomas and discoloration showed improvement. In addition, lipid levels and serum lycopene had returned to normal.
  
  
  CONCLUSIONS
  All cases of lycopenaemia reported in the literature followed excessive ingestion of lycopene in foods. We describe the first case of lycopenaemia with orange discoloration of xanthomas following raised serum lycopene but not involving excessive dietary intake. Type-III HLP was doubtless instrumental in the physiopathogenesis of these orange lesions.
authors.affiliation: Service de dermatologie, université Paul-Sabatier, CHU Toulouse-Purpan, 1, place du Dr-Baylac, Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Royer
authors.forename: C
authors.initials: C
authors.lastname: Bulai Livideanu
authors.forename: B
authors.initials: B
authors.lastname: Periquet
authors.forename: P
authors.initials: P
authors.lastname: Maybon
authors.forename: L
authors.initials: L
authors.lastname: Lamant
authors.forename: J
authors.initials: J
authors.lastname: Mazereeuw-Hautier
authors.forename: J
authors.initials: J
authors.lastname: Ferrières
authors.forename: C
authors.initials: C
authors.lastname: Paul
mesh_terms: D001384:Azetidines / Q000627:therapeutic use; D002338:Carotenoids / Q000097:blood*; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000150:complications*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D000077276:Lycopene; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use; D010859:Pigmentation Disorders / Q000188:drug therapy / Q000209:etiology*; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology*; D014973:Xanthomatosis / Q000188:drug therapy / Q000209:etiology*
chemical_list: D001384:Azetidines; D000960:Hypolipidemic Agents; D009525:Niacin; D002338:Carotenoids; D000069438:Ezetimibe; D000077276:Lycopene